Close

Elligo Health Research Launches Novel IntElligo Research Stack Clinical Technology

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Small Molecule API Market Growth Analysis and Future Trends

Small Molecule API Market Size, Share, and Growth Analysis The...

Reviving Old Drugs with Specialty Intermediates in Europe

Drug development in the European pharmaceutical industry is undergoing...

Specialty Chemicals Solubility Enhances Drug Formulations

The need to improve the effectiveness, safety, and accessibility...

Rina-S Shows Promise in Advanced Ovarian Cancer

Genmab has reported encouraging findings from the Phase 2...

Elligo Health Research, an integrated research organization (IRO), announces the launch of its innovative IntElligo Research Stack™ clinical technology.

This standards-based technology platform, which powers the System of Accelerated Research (SOAR™) model, will be launched this month as the eSource documentation tool at Elligo’s Research Ready network of study sites.

 ”IntElligo can be set up per the study protocol in hours and easily follows the workflow in any physician’s office,” said Jacylyn Bodmer, Elligo’s chief information officer. “We are improving data quality while relieving administrative burden at the research site and enabling more patient-centric interactions. IntElligo also facilitates remote monitoring, which results in faster source data verification and financial payments to our physicians.”                                                                                                                                  

“IntElligo bridges health care and research, leveraging global industry standards from the start (CDISC PRM and CDASH), thus facilitating aggregation and tabulation into CDISC SDTM, the required format for regulatory eSubmissions to the FDA and Japan’s PMDA,” added Rebecca Kush, Ph.D., Elligo’s chief scientific officer.

In addition, the technology provides real-time management financial management, reports, and analytics across research sites; saves time and preserves data integrity by eliminating transcription; and, achieves true eSource. Furthermore, it creates the opportunity to transform research through the SOAR™ model — expanding patient access and driving efficiency by enabling direct data from source to submission.  

“By uniting our Goes Direct® approach with this technology and infrastructure to support physicians, we are creating the ultimate solution for clinical trial execution,” said John Potthoff, Ph.D., Elligo CEO. “The IntElligo platform will become a primary resource for our study sites, increasing the ability for physicians to provide research as a care option and enabling more patients to benefit.” 

About Elligo
Elligo Health Research, an integrated research organization, accelerates the development of new pharmaceutical, biotechnology, medical device, and diagnostic products using our novel IntElligo Research Stack™ clinical technology and our Goes Direct® approach. We unite the best clinical experts with the best research infrastructure — creating the ultimate clinical trial solution. By maintaining the integrity of the trusted patient and physician relationship and building global communities of research that leverage electronic health records, we ensure all patients have access to clinical trials as a care option. Learn more at elligodirect.com

Latest stories

Related stories

Small Molecule API Market Growth Analysis and Future Trends

Small Molecule API Market Size, Share, and Growth Analysis The...

Reviving Old Drugs with Specialty Intermediates in Europe

Drug development in the European pharmaceutical industry is undergoing...

Specialty Chemicals Solubility Enhances Drug Formulations

The need to improve the effectiveness, safety, and accessibility...

Rina-S Shows Promise in Advanced Ovarian Cancer

Genmab has reported encouraging findings from the Phase 2...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back